Core Lithium resumes Finnis mining, Ktek drone IPO doubles, short sellers target 4D Medical, Arafura rare earths FID with capital raise. Which setups have legs?
Alpha Score of 59 reflects moderate overall profile with strong momentum, strong value, weak quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
The ASX wrapped a mixed week with a clear pattern: production restarts in lithium, two new listings in defence tech and retail, and short-seller pressure on high-multiple biotechs. Each story carries a mechanism that matters for the weeks ahead, not just a headline.
Core Lithium recommenced mining at its Finnis project this week. The decision followed an uptick in lithium prices over recent months. MinRes also resumed mining at its Bald Hill project in the same period. The two restarts within days signal that lithium prices have crossed a threshold where marginal production becomes viable again.
The restarts are a supply signal. When two producers flip the switch almost simultaneously, the market reads it as a sector-level floor for lithium prices. The question is whether the price recovery has enough runway to absorb additional tonnes. If spot lithium prices hold or rise over the next two quarters, the restarts look smart. If prices stall, Core Lithium and MinRes risk adding supply into a still-oversupplied market.
Ktek Aerosystems, an Israeli-backed drone technology company, made its ASX debut and rocketed above its listing price. As of Friday, the stock held a one-week gain of 100%.
Investor interest was predictable. Droneshield and Electro Optic both rewarded early movers in the same sector. Ktek is the latest entrant in a defence and drone technology theme that has momentum. The stock's doubling in the first week reflects demand for exposure, not necessarily a deep understanding of Ktek's specific revenue pipeline.
The stock has no meaningful newsflow beyond the listing itself. The first contract win, earnings disclosure, or operational update will be the real test. A 100% gain in week one sets a high bar. Investors watching Ktek should treat the current price as a sentiment premium until the company delivers tangible results.
SkinKandy, a company that owns skin piercing stores on Australia's east coast, joined the ASX this week. Like Guzman Gomez and Koala before it, SkinKandy hit the bourse with plans for international expansion. The stock locked in 12% gains since listing as of Friday.
A 12% first-week gain is modest compared to Ktek's 100%. SkinKandy is a retail business with existing store-level economics. The gain suggests the market is pricing in the expansion story without overpaying.
The international expansion plan is the key variable. SkinKandy's current footprint is concentrated on the east coast of Australia. Scaling that model overseas introduces execution risk, currency exposure, and regulatory differences. The stock's performance over the next six months will depend on whether the company can articulate a credible path to international revenue without burning cash.
4D Medical has been a HotCopper favourite for months. The tone shifted this week. The stock's share price faltered as short sellers increased pressure. The company carries a market capitalisation of $2 billion with little meaningful revenue.
Short sellers are circling a stock that trades on promise rather than earnings. A $2B market cap with minimal revenue is a natural target for short interest. The share price decline reflects that pressure, not necessarily a change in the underlying technology or regulatory path.
Bulls argue that the technology is transformative and that revenue will follow regulatory approvals. Bears point to the lack of current revenue and the high valuation as a setup for a correction. The next catalyst is likely a regulatory or commercial milestone. Until then, the short sellers have the momentum.
Practical rule: When a stock with minimal revenue has a $2B market cap, short sellers will test the thesis until revenue materializes.
Arafura Rare Earths, backed by Gina Rinehart, announced a positive final investment decision (FID) on its Nolans rare earth project in the Northern Territory. At nameplate capacity, Nolans will be Australia's next major rare earths mine. The good news was followed on Friday by an announcement of another capital raise.
The sequencing matters. A positive FID validates the project's economics. A capital raise in the same week signals that the company needs external funding to execute that FID. The two events together create a mixed message: the project is greenlit, existing shareholders will be diluted.
Investor sentiment on Arafura came down to how one views the glass. Optimists see the FID as the key de-risking event and the raise as a necessary step to build the mine. Pessimists see the raise as a sign that the company cannot fund the project from cash flow or debt alone. The stock's reaction in the coming weeks will reveal which view prevails.
Lumos Diagnostics, another biotech darling, is in the hot seat. Year-to-date returns for the diagnostic technology company are down 56% at 12.5 cents per share. That still represents a twelve-month return of nearly +400%. The recent trajectory has investors nervous.
The drop from the peak is sharp. A 56% decline in five months suggests the market is repricing the stock after a speculative run. The current price of 12.5cps is well above levels from a year ago.
The 400% annual return is a reminder that timing matters. Investors who bought a year ago are still sitting on large gains. Those who bought at the peak are underwater. The stock's future depends on whether the company can deliver commercial traction that justifies a higher valuation. Until then, the downward pressure may continue.
For a broader view of how these themes fit into the current market environment, see our stock market analysis section. The ASX week 21 recap shows that the market is rewarding clear catalysts–lithium restarts, defence IPOs, and rare earths milestones–while punishing stocks that rely on narrative without revenue. The next few weeks will separate the setups that have legs from those that are already priced in.
Prepared with AlphaScala editorial tooling from the source reporting linked above. Indexable analysis may include a cited Alpha Score value. Publishing checks screen each story before release. Educational coverage, not personalized advice.